Phospholipase A2 enzymes and the risk of atherosclerosis
about
Antioxidant properties of HDLTesting cardiovascular drug safety and efficacy in randomized trialsSecretory phospholipase-A2 and fatty acid composition in oral reactive lesions: a cross-sectional studySecretory phospholipase A2 enzymes as pharmacological targets for treatment of diseaseNovel cardiovascular risk markers in women with ischaemic heart disease.Anti-inflammatory therapies for cardiovascular diseaseLipoprotein-associated phospholipase A₂ is related to plaque stability and is a potential biomarker for acute coronary syndrome.Alterations of plasma lysophosphatidylcholine species in obesity and weight loss.Membranes serve as allosteric activators of phospholipase A2, enabling it to extract, bind, and hydrolyze phospholipid substratesRedox regulation of NLRP3 inflammasomes: ROS as trigger or effector?Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in AtherosclerosisNeutrophil effector responses are suppressed by secretory phospholipase A2 modified HDL.Antipsoriatic treatment extends beyond the skin: recovering of high-density lipoprotein functionMembrane and inhibitor interactions of intracellular phospholipases A2.Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.Refined purification strategy for reliable proteomic profiling of HDL2/3: Impact on proteomic complexity.Fatty acid epoxyisoprostane E2 stimulates an oxidative stress response in endothelial cells.Emerging anti-inflammatory drugs for atherosclerosis.Molecular biology of atherosclerosis.Effect of lysophosphatidylglycerol on intracellular free Ca2+ concentration in A10 vascular smooth muscle cells.Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection.Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?Discovery of AZD2716: A Novel Secreted Phospholipase A2 (sPLA2) Inhibitor for the Treatment of Coronary Artery Disease.Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.Secretory phospholipase A2 modified HDL rapidly and potently suppresses platelet activationDeposition and hydrolysis of serine dipeptide lipids of Bacteroidetes bacteria in human arteries: relationship to atherosclerosis.Evaluation of Bacillus subtilis SPB1 biosurfactant effects on hyperglycemia, angiotensin I-converting enzyme (ACE) activity and kidney function in rats fed on high-fat-high-fructose diet.Lipoprotein-associated phospholipase A2 and oxidized low-density lipoprotein in young patients with acute coronary syndrome in China.Thrombosis and Vascular Inflammation in Diabetes: Mechanisms and Potential Therapeutic Targets.New quinoxalinone inhibitors targeting secreted phospholipase A2 and α-glucosidase.
P2860
Q26777244-105C922F-1E2B-4A64-AEE5-8748EC6DA294Q26849771-ECE6359B-23F2-458D-8265-2FF13E6860CCQ33612945-92FCD2B4-2B91-4954-B99F-58EC733FF3DAQ33923169-B3247D21-248A-4774-ABF6-B021728C7514Q33995037-ED8454C7-A200-48FF-977C-15CEDB92F47FQ34137872-39756119-B639-4705-9CE5-4B3E3724555FQ34384281-D996206C-494D-4F8D-B248-E7083BC9B285Q34395775-95B5BD70-1601-4B78-8C5D-D513521BAA4DQ35090044-95FFAE6A-04E4-4599-A183-5ADD66951E25Q35486035-10B8E331-326F-4F6C-B0AA-9AE3DBD4F5DAQ36541529-537D1B6A-1943-4309-A04E-CB02950615A2Q36681188-26FAA2BF-AB69-4E22-A29B-E760A81B526AQ36681220-6851331A-C350-4DE7-8170-0FA0BE962A24Q36945608-8E372826-C2A9-4355-93BE-E7C117F08266Q37303915-6CB2D2E1-46C8-410D-A2E7-FDBCB7F59328Q37472192-34948B14-8A82-4B5C-945E-8B682AB18F14Q37656413-63636624-1EB9-418D-A675-3302C5F03167Q38106998-73F52B08-2FF8-400C-8EAD-E2E79C205332Q38125279-246E5CD4-265B-4505-9796-C4025D439703Q38696743-6AE75489-0B80-4EAC-85B0-33F610174612Q38707328-47F5D419-7B37-4422-881C-580FDC2DBC76Q38836998-20256D9A-2F93-42CB-85C4-5C73A7265426Q39256623-A729B2E9-7878-4A06-B961-BE8BE410AC8CQ41115717-8105E373-4402-4135-A0A2-ADDD24B9C744Q41387814-A727D7FE-86DC-42CC-B480-964DA4DAD98CQ42005277-73AE679E-FA06-403F-93CA-8B51062EB8ADQ46494784-C3C50502-39E8-4361-8FCF-74EF84C10678Q47137236-7C19817E-519E-436A-AE3C-991D3727EFC2Q48512017-2E16F880-D591-4E9D-A583-A9DF07B2AFE9Q50252284-BD21A43F-AB9D-45FD-BC01-8EF4859B9123
P2860
Phospholipase A2 enzymes and the risk of atherosclerosis
description
2012 nî lūn-bûn
@nan
2012 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Phospholipase A2 enzymes and the risk of atherosclerosis
@ast
Phospholipase A2 enzymes and the risk of atherosclerosis
@en
Phospholipase A2 enzymes and the risk of atherosclerosis
@nl
type
label
Phospholipase A2 enzymes and the risk of atherosclerosis
@ast
Phospholipase A2 enzymes and the risk of atherosclerosis
@en
Phospholipase A2 enzymes and the risk of atherosclerosis
@nl
prefLabel
Phospholipase A2 enzymes and the risk of atherosclerosis
@ast
Phospholipase A2 enzymes and the risk of atherosclerosis
@en
Phospholipase A2 enzymes and the risk of atherosclerosis
@nl
P356
P1476
Phospholipase A2 enzymes and the risk of atherosclerosis
@en
P2093
E. Hurt-Camejo
R. S. Rosenson
P304
P356
10.1093/EURHEARTJ/EHS148
P407
P577
2012-12-01T00:00:00Z